Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Jan 16;279(3):1637-42.
doi: 10.1074/jbc.M310875200. Epub 2003 Oct 15.

Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase

Affiliations

Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase

Keqiang Fan et al. J Biol Chem. .

Abstract

The 3C-like proteinase of severe acute respiratory syndrome (SARS) coronavirus has been proposed to be a key target for structural-based drug design against SARS. In order to understand the active form and the substrate specificity of the enzyme, we have cloned, expressed, and purified SARS 3C-like proteinase. Analytic gel filtration shows a mixture of monomer and dimer at a protein concentration of 4 mg/ml and mostly monomer at 0.2 mg/ml, which correspond to the concentration used in the enzyme assays. The linear decrease of the enzymatic-specific activity with the decrease of enzyme concentration revealed that only the dimeric form is active and the dimeric interface could be targeted for structural-based drug design against SARS 3C-like proteinase. By using a high pressure liquid chromatography assay, SARS 3C-like proteinase was shown to cut the 11 peptides covering all of the 11 cleavage sites on the viral polyprotein with different efficiency. The two peptides corresponding to the two self-cleavage sites are the two with highest cleavage efficiency, whereas peptides with non-canonical residues at P2 or P1' positions react slower. The P2 position of the substrates seems to favor large hydrophobic residues. Secondary structure studies for the peptide substrates revealed that substrates with more beta-sheetlike structure tend to react fast. This study provides a basic understanding of the enzyme catalysis and a full substrate specificity spectrum for SARS 3C-like proteinase, which are helpful for structural-based inhibitor design against SARS and other coronavirus.

PubMed Disclaimer

Figures

F<sc>ig</sc>. 1
Fig. 1
Expression and purification of the SARS 3C-like proteinase. Samples taken at each step of purification were analyzed on a 12% SDS-polyacrylamide gel, and the protein was stained with Coomassie Brilliant Blue. Lane M, protein molecular mass marker; lanes 1 and 2, cell lysates from non-induced and isopropyl-1-thio-β-d-galactopyranoside-induced E. coli BL21(DE3) containing the expression plasmid pET 3CLP-21x; lanes 3 and 4, the supernatant and the deposition separated from the cell lysate by centrifugation; lane 5, collected peak fractions from the nickel-nitrilotriacetic acid column; lane 6, collected peak fractions from the Sephacryl S-200 HR column.
F<sc>ig</sc>. 2
Fig. 2
CD spectra of SARS 3C-like proteinase. The CD spectra of 3C-like proteinase were recorded in 40 mm Tris-HCl buffer, pH 8.0 at 20 °C. a, far-UV CD spectrum shows a positive peak at 196 nm and two negative peaks at 209 and 222 nm, respectively, indicating a mixed α and β structure. b, near-UV CD spectrum shows a broad positive peak at ∼280 nm and a small positive shoulder at 291 nm. c, thermal melting of the protein by monitoring the CD signal at 218 nm gives a sigmoid denaturation curve and a Tm of 61 °C
F<sc>ig</sc>. 3
Fig. 3
Aggregation state of SARS 3C-like proteinase on analytic gel filtration column. Superdex 75 HR column was used on ÄKTA fast protein liquid chromatography for the analysis. Solid line, 4 mg/ml; dot-and-dash line, 0.2 mg/ml. Two peaks corresponding to monomeric and dimeric states were detected at 4 mg/ml, whereas at 0.2 mg/ml, only one peak corresponding to the monomeric state appears.
F<sc>ig</sc>. 4
Fig. 4
Enzyme activity of SARS CoV 3C-like proteinase at different concentrations. The proteolysis activity of expressed SARS CoV 3C-like proteinase at different concentrations was determined by incubating 0.2 mm S01 with 3C-like proteinase in 40 mm Tris-HCl buffer, pH 7.3. The observed kcat/Km increases in a linear manner, whereas the enzyme concentration increases, indicating the dimer form is the active form of the proteinase.
F<sc>ig</sc>. 5
Fig. 5
Enzyme activity of SARS CoV 3C-like proteinase at different pH values. The proteolysis activity of expressed SARS CoV 3C-like proteinase at different pH values was determined in citric acid/phosphate buffer (pH 5, 6, 7, and 8) or glycine/NaOH buffer (pH 9 or 10) containing 6.8 mm dithiothreitol, 2 mm S01 as substrate, and 2.14 μm 3C-like proteinase.
F<sc>ig</sc>. 6
Fig. 6
The relationship of secondary structure contents in substrate peptides with cleavage efficiency.a, far-UV CD spectra of peptide substrates. ♦, S01; •, S02; ▴, S05; ▾, S07; and ▪, S11. b, calculated content of secondary structure versus kcat/Km profile. This figure shows an interesting tendency of which substrate peptide with small kcat/Km has relatively less content of sheet (▪) but more content of unordered structure (○), suggesting that the formation of β-strandlike extended structure is favored for binding to the enzyme and proteolysis.

Similar articles

Cited by

References

    1. Drosten C., Gunther S., Preiser W., van der W.S., Brodt H.R., Becker S., Rabenau H., Panning M., Kolesnikova L., Fouchier R.A., Berger A., Burguiere A.M., Cinatl J., Eickmann M., Escriou N., Grywna K., Kramme S., Manuguerra J.C., Muller S., Rickerts V., Sturmer M., Vieth S., Klenk H.D., Osterhaus A.D., Schmitz H., Doerr H.W. N. Engl. J. Med. 2003;348:1967–1976. - PubMed
    1. Ksiazek T.G., Erdman D., Goldsmith C.S., Zaki S.R., Peret T., Emery S., Tong S., Urbani C., Comer J.A., Lim W., Rollin P.E., Dowell S.F., Ling A.E., Humphrey C.D., Shieh W.J., Guarner J., Paddock C.D., Rota P., Fields B., DeRisi J., Yang J.Y., Cox N., Hughes J.M., LeDuc J.W., Bellini W.J., Anderson L.J. N. Engl. J. Med. 2003;348:1953–1966. - PubMed
    1. Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R., Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.H., Tong S., Tamin A., Lowe L., Frace M., DeRisi J.L., Chen Q., Wang D., Erdman D.D., Peret T.C., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S., Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R., Gunther S., Osterhaus A.D., Drosten C., Pallansch M.A., Anderson L.J., Bellini W.J. Science. 2003;300:1394–1399. - PubMed
    1. Marra M.A., Jones S.J., Astell C.R., Holt R.A., Brooks-Wilson A., Butterfield Y.S., Khattra J., Asano J.K., Barber S.A., Chan S.Y., Cloutier A., Coughlin S.M., Freeman D., Girn N., Griffith O.L., Leach S.R., Mayo M., McDonald H., Montgomery S.B., Pandoh P.K., Petrescu A.S., Robertson A.G., Schein J.E., Siddiqui A., Smailus D.E., Stott J.M., Yang G.S., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K., Booth T.F., Bowness D., Czub M., Drebot M., Fernando L., Flick R., Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A., Kabani A., Li Y., Normand S., Stroher U., Tipples G.A., Tyler S., Vogrig R., Ward D., Watson B., Brunham R.C., Krajden M., Petric M., Skowronski D.M., Upton C., Roper R.L. Science. 2003;300:1399–1404. - PubMed
    1. Anand K., Palm G.J., Mesters J.R., Siddell S.G., Ziebuhr J., Hilgenfeld R. EMBO J. 2002;21:3213–3224. - PMC - PubMed

Uncited references

    1. Deleted in proof

Publication types

MeSH terms